

STN - Structure Search

-Registry/Caplus

10/563,089


02/28/2007

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



$$R_1, R_2, R_3 = G_1 = O, N, Ak \checkmark$$

G1 O, N, Ak

G2 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 09:38:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2549 TO ITERATE100.0% PROCESSED 2549 ITERATIONS
SEARCH TIME: 00.00.01

L2 181 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COSTSINCE FILE
ENTRY
172.55
TOTAL
SESSION
172.76FILE 'CAPLUS' ENTERED AT 09:38:36 ON 28 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12
L3 22 L2

=> d ibib abs hitstr 1-22

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 200714089 CAPLUS

DOCUMENT NUMBER: 146120341

TITLE: Manufacture of anti-HCV drugs with Fusarium
INVENTOR(S): Aoki, Masahiro; Nagashishi, Yoshie; Kato, Hideyuki;
Ito, Tatsuya; Masubuchi, Miyako; Okuda, Toru
Chugai Seiyaku Kabushiki Kaisha, Japan

PATENT ASSIGNEE(S): PCT Int. Appl., 81pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000994	A1	20070104	WO 2006-JP312798	20060627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	M: AR, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	W: AR, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	JP 2005-188765	A 20050628
PRIORITY APPN. INFO.:				

OTHER SOURCE(S): MARPAT 146:120541
GI

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



AB It is intended to provide a simple and inexpensive method of producing a compound which has a high activity of inhibiting replication of hepatitis C virus (HCV) and is useful for preventing and treating a liver disease caused by HCV infection. It is a method of biol. producing a compound

(I: A = H, linear or branched C1-8 alkyl group) or a pharmaceutical acceptable salt with II-producing Fusarium incarnatum from amino acid deriva. The morphol. and physiol. characteristics of the F. incarnatum were also given.

IT 827034-92-4 827035-10-9 827035-62-1P

RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP

(Preparation); (Manufacture of anti-HCV drugs with Fusarium from amino acid deriva.)


RN 827034-92-4 CAPLUS

CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-(2-butynyloxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.


L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-10-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(3-pyridinyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-62-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—OME

RN 827035-65-4 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(2'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 876404-54-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-((3-methyl-2-butenyl)oxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: THIS

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:843652 CAPLUS
 DOCUMENT NUMBER: 145:272019
 TITLE: Process for producing compound with anti-HCV potency and intermediate for use therein
 INVENTOR(S): Kato, Tatsuya; Kimura, Nobuaki; Mizutani, Akemi; Makino, Toshihiko; Kawasaki, Kenichi; Fukuda, Hiroshi;
 PATENT ASSIGNEE(S): Komiyama, Susumu; Tsukuda, Taku; Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 112pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088071	A1	20060824	WO 2006-JP302687	20060216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		JP 2005-41153		A 20050217

OTHER SOURCE(S): MARPAT 145:272019
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A process for the preparation of the compd. of formula I [Y = (un)substituted 2-oxazolidinonyl or 2-oxazolidinethionyl; Q = protected carbonyl; m = 0-10; n = 0-10; R' = H, (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl or heterocycl; P = OH protecting group] comprising reacting a compound of formula II [Y, Q, R', m and n are defined as above] with a compound of formula III [P = OH protecting group; P' = protecting group of carboxyl] is disclosed. For example, IV was provided in a multi-step synthesis starting from monomethyl azellic acid. I have a desirable optical activity and can be synthesized selectively in high yield through a reduced number of steps, they may be useful as inhibitors of HCV replication
 (no data, no claim).
 IT 906651-47-6P 906651-49-8P 906651-55-6P

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 101-83-7
 CNF C12 H23 N



RN 906651-55-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-1-[(4-(2-butynyoxy)phenyl)methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-58-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy-1,1'-biphenyl)-4-yl)methyl]-2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Searched by Jason M. Nolan, Ph.D.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 906651-58-9P 906651-59-0P 906651-63-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of L-tyrosine derivs. with anti-HCV potency and their intermediates)
 RN 906651-47-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-1-[(4-(2-butynyoxy)phenyl)methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 906651-49-8 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-1-[(4-(2-butynyoxy)phenyl)methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 906651-47-6
 CNF C43 H65 N O10

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-59-0 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy-1,1'-biphenyl)-4-yl)methyl]-2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 906651-58-9
 CNF C46 H67 N O10

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 101-83-7
 CMF C12 H23 N



RN 906651-63-6 CAPLUS
 CN D-erythro-Pentonic acid,
 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-
 5-[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-
 2-oxoethyl]amino-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-
 oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-64-7 CAPLUS
 CN D-erythro-Pentonic acid,
 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-
 5-[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-
 2-oxoethyl]amino-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-
 oxo-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX
 NAME)

CM 1


CRN 906651-63-6
 CMF C48 H71 N O11

Absolute stereochemistry.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.




CM 2
 CRN 101-83-7
 CMF C12 H23 N



IT 827034-92-4P 827035-62-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of L-tyrosine derivs. with anti-HCV potency and their
 intermediates)
 RN 827034-92-4 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-(4-(2-butynyl)phenyl)-1-
 carboxyethyl]amino-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-62-1 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-methoxy[1,1'-
 biphenyl]-4-yl)ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

OMe

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:646516 CAPLUS
 DOCUMENT NUMBER: 145:271525
 TITLE: A Simple, Short, and Flexible Synthesis of
 Viridifungin Derivatives
 AUTHOR(S): Goldup, Stephen M.; Pilkington, Christopher J.;
 CORPORATE SOURCE: Andrew J. P.; Burton, Andrew; Barrett, Anthony G. M.;
 Department of Chemistry, Imperial College London, London, SW7 2AZ, UK
 SOURCE: 6185-6191
 PUBLISHER: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: American Chemical Society
 Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:271525
 GI




AB Described herein is a simple, flexible, and efficient synthesis of the skeleton of the viridifungins, a family of microbial secondary metabolites. The synthesis utilizes asym. aldol reaction of chiral oxazolidinone I with Et glyoxalate, diastereoselective alkylation of chiral 1,3-dioxolan-2-one II with tert-Bu bromoacetate, and a geometrically selective alkene cross-metathesis reaction as the key C-C bond-forming steps.

IT 907189-17-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of viridifungins with vinyl malate and vinyl citrate
 as key intermediates via stereoselective aldol addition, enolate
 alkylation and cross metathesis)

RN 907189-17-7 CAPLUS
 CN L-Tyrosine,
 N-(2,4-dideoxy-5-O-(1,1-dimethylethyl)-3-C-(methoxycarbonyl)-5-
 C-oxo-2-((1E)-9-oxo-1-hexadecenyl)-L-erythro-pentonoyl)-O-(1,1-
 dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.


L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:268345 CAPLUS
DOCUMENT NUMBER: 144:310621
TITLE: Anti-HCV compounds and their medical compositions
INVENTOR(S): Aoki, Masahiro; Kato, Hideyuki; Ito, Tatsuya; Itexono,
Keiko; Sudo, Masayuki
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006077004	A	20060323	JP 2005-231587	20050810
			JP 2004-234699	A 20040811
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):		MARPAT 144:310621		
GI				



AB Claimed are title compds. I [R1-R3 = H, OH, (un)substituted NH₂, C1-4 linear or branched alkyl(oxy), C2-4 linear or branched alkenyl(oxy), C2-4 alkyanyl(oxy); A = H, (un)substituted C5 linear or branched alkenyl; B = H, (un)substituted NH₂, (un)substituted MOH, etc.; C = (un)substituted linear or branched C7 alkyl, alkenyl, alkyanyl; Q = single or double bond; when A = H or alkenyl, then C = (OH-substituted) linear or branched C7 alkenyl or 2-hydroxy-n-heptyl], their prodrugs, or pharmacol. acceptable salts. Thus, Fusarium sp. F1476 was shake-cultured in a medium containing glucose, glycerin, potato starch, etc., to manufacture II, which inhibited replicon with IC₅₀ value of 956 nM and cytotoxicity CC₅₀ value of 7400 nM.
IT 879872-40-9P 879872-41-OP 879872-42-1P
879873-72-0P 879873-73-1P 879873-74-2P
879873-75-3P
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); PAC


L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(manuf. of tyrosines as anti-HCV agents with Fusarium sp.)
RN 879872-40-9 CAPLUS
CN L-Tyrosine,
N-[(19,3E)-2-[(18)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3-octadecenyl]-O-[(2E)-4-hydroxy-3-methyl-2-but enyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879872-41-0 CAPLUS
CN L-Tyrosine, N-[(19,3E,12E)-2-[(18)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3,12-octadecadienyl]-O-(3-methyl-2-but enyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B


L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN L-Tyrosine,
N-[(1S,3E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3-octadecenyl]-O-[(2Z)-4-hydroxy-3-methyl-2-but enyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879873-72-0 CAPLUS
CN L-Tyrosine, N-[(2S,3E,13E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-11,12-dihydroxy-1-oxo-3,13-octadecadienyl]-O-(3-methyl-2-but enyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.




RN 879873-73-1 CAPLUS
CN L-Tyrosine, N-[3-C-carboxy-2,4-dideoxy-2-[(1E)-11-hydroxy-9-oxo-1-hexadecenyl]-5-C-oxo-L-erythro-pentenoyl]-O-(3-methyl-2-but enyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.

Me


RN 879872-42-1 CAPLUS

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 745782-40-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxohexadecyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 827034-86-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827034-88-8 CAPLUS

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-90-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-phenylmethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-92-4 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(2-butynyloxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827034-94-6 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-[1,1'-biphenyl]-4-yl-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-96-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-naphthalenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-98-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyclohexyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hexadecenyl- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-00-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methylpentyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-02-9 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3,4-dimethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-04-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-chlorophenoxy)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-06-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(4-fluorophenoxy)ethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-08-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-pentylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827035-10-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-pyridinyl)phenylethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-12-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-chlorobiphenyl)-4-yl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-14-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-biphenyl)-4-yl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-16-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2',4'-difluorobiphenyl)-4-yl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Me


RN 827035-18-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-thienyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-20-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(trifluoromethyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-21-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyanophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 827035-23-4 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-chlorophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-25-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-nitrophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)


RN 827035-29-0 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(1,1'-biphenyl)-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-30-3 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-chlorophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-31-4 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-butoxypyhenyl)-1-carboxyethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 827035-27-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-thienyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-28-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(1,1-dimethylethyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 827035-32-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-propoxypyhenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-33-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(2-propenyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-34-7 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-35-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-11-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-36-9 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecadienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-41-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1,15-hexadecadienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-42-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-heptadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-43-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-14-methyl-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-38-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-40-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-11-phenyl-1-undecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-45-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-46-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-4-[(1E)-11-cyclohexyl-9-oxo-1-undecenyl]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-A

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

PAGE 1-B



RN 827035-50-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-methoxyphenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 876344-57-9 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenoxy)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 876344-58-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-2,4,5-trideoxy-5-[(1S)-2-methoxy-1-[(4-(3-methylphenoxy)phenyl)methyl]-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 876344-59-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenoxy)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-10-hydroxy-9-oxo-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 876344-60-4 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 876344-61-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenoxy)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-9-hydroxy-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 876344-62-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-(aminocarbonyl)-5-[(1S)-1-carboxy-2-[4-((3-


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methyl-2-butenoxy)oxyphenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 876344-63-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenoxy)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 876344-64-8 CAPLUS
CN D-erythro-Pentonic acid, 4-[(1E)-9-[(2-aminoethoxy)imino]-1-hexadecenyl]-3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenoxy)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as described by E or Z.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT:
FORMAT

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE



RN 876344-65-9 CAPLUS

CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-((1E)-9-(methoxyimino)-1-
hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as described by E or Z.

RN 876404-34-5 CAPLUS

CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-
butenyl)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-
hexadecenyl)- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1148778 CAPLUS

DOCUMENT NUMBER: 144:63941

TITLE: Host sphingolipid biosynthesis as a target for
hepatitis C virus therapyAUTHOR(S): Sakamoto, Hiroshi; Okamoto, Koichi; Aoki, Masahiro;
Kato, Hideyuki; Katsume, Asao; Ohta, Atsunori;Tsukuda, Takuo; Shimma, Nobuo; Aoki, Yuko; Arisawa,
Mikio; Kohara, Michinori; Sudoh, MasayukiCORPORATE SOURCE: Kamakura Research Laboratories, Chugai Pharmaceutical
Co. Ltd., Kamakura, Kanagawa, 247-8530, Japan

SOURCE: Nature Chemical Biology (2005), 1(6), 333-337

CODEN: NCBABT; ISSN: 1552-4450

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An estimated 170 million individuals worldwide are infected with

hepatitis C virus (HCV), a serious cause of chronic liver disease. Current
interferon-based therapy for treating HCV infection has an unsatisfactory
cure rate, and the development of more efficient drugs is needed. During
the early stages of HCV infections, various host genes are differentially
regulated, and it is possible that inhibition of host proteins affords a
therapeutic strategy for treatment of HCV infection. Using an HCV
subgenomic replicon cell culture system, here we have identified, from a
secondary fungal metabolite, a lipophilic long-chain base compound, NA255
(1), a previously unknown small-mol. HCV replication inhibitor. NA255
prevents the de novo synthesis of sphingolipids, major lipid raft
components, thereby inhibiting serine palmitoyltransferase, and it
disrupts the association among HCV nonstructural (NS) viral proteins onthe
lipid rafts. Furthermore, we found that NS5B protein has a
sphingolipid-binding motif in its mol. structure and that the domain was
able to directly interact with sphingomyelin. Thus, NA255 is a new
anti-HCV replication inhibitor that targets host lipid rafts, suggesting
that inhibition of sphingolipid metabolism may provide a new therapeutic
strategy for treatment of HCV infection.

IT 745782-39-2P, NA 255

RL: DMA (Drug mechanism of action); NPO (Natural product occurrence); PAC
(Pharmacological activity); PUR (Purification or recovery); THU
(Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); USES (Uses)
(host sphingolipid biosynthesis as target for hepatitis C virus
therapy)


RN 745782-39-2 CAPLUS

CN D-erythro-Pentonic acid,

3-C-carboxy-5-[(1S)-1-carboxy-2-[4-((3-methyl-2-
butenyl)oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((9-oxo-1-
hexadecenyl)- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

REFERENCE COUNT:
FORMAT28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR
RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005529464 CAPLUS

DOCUMENT NUMBER: 143:193833

TITLE: Ester Dienolate [2,3]-Wittig Rearrangement in Natural Product Synthesis: Diastereoselective Total Synthesis of the Triester of Viridiofungin A, A2, and A4

AUTHOR(S): Pollex, Annett; Millet, Agnes; Mueller, Jana;

Hiersemann, Martin; Abraham, Lars

CORPORATE SOURCE: Institut fuer Organische Chemie, Technische Universitaet Dresden, Dresden, 01062, Germany

SOURCE: Journal of Organic Chemistry (2005), 70(14),

5579-5591

PUBLISHER: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: American Chemical Society

LANGUAGE: Journal

OTHER SOURCE(S): English

CASREACT 143:193833

GI

STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB An ester dianolate [2,3]-Wittig rearrangement was utilized to access the alkylated citric acid skeleton I that is characteristic for the viridiofungins and other members of the alkyl citrate family of secondary natural products. The [2,3]-sigmatropic rearrangement of II provided the rearrangement product I in moderate yield and with very good diastereoselectivity. A Julia-Kocienski olefination efficiently served

to connect the polar head III with the lipophilic tail, e.g. IV of the viridiofungins. Amide formation between the racemic viridiofungin precursors, e.g. V, and the enantiomerically pure amino acid L-Tyrosine

Me ester followed by preparative reversed-phase HPLC provided the iso-Pr di-Me ester of viridiofungin A (VI), A2, and A4 as well as nonnatural diastereomers.

IT 777891-06-2P 861997-63-9P 861997-92-4P

861997-93-5P 861997-94-6P 861997-95-7P

RL: SPP (Synthetic preparation); PREP (Preparation)

(diastereoselective total synthesis of the triester of viridiofungin A,

A2, and A4 via ester dianolate [2,3]-Wittig rearrangement)

RN 777891-06-2 CAPLUS

CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-

oxo-2-[(1E)-9-oxo-1-hexadecenyl]-D-erythro-pentonoyl], methyl ester


(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 861997-63-9 CAPLUS

CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-

(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.



RN 861997-92-4 CAPLUS


CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-

(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 861997-93-5 CAPLUS

CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-

(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



RN 861997-94-6 CAPLUS


CN L-Tyrosine, N-[2,4-dideoxy-2-(1E)-1-hexadecenyl-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-D-erythro-pentonoyl], methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 861997-95-7 CAPLUS

CN L-Tyrosine, N-[2,4-dideoxy-2-(1E)-1-hexadecenyl-5-O-methyl-3-C-[(1-

methylethoxy)carbonyl]-5-C-oxo-L-erythro-pentonoyl], methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-). Double bond geometry as shown.




REFERENCE COUNT:

THIS

63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:458825 CAPLUS
 DOCUMENT NUMBER: 143:115373
 TITLE: Total synthesis of viridiofungin A
 AUTHOR(S): Morokuma, Kenji; Takahashi, Keisuke; Ishihara, Jun;
 Hatakeyama, Susumu
 CORPORATE SOURCE: Graduate School of Biomedical Sciences, Nagasaki
 University, Nagasaki, 852-8521, Japan
 SOURCE: Chemical Communications (Cambridge, United Kingdom) (2005), (17), 2265-2267
 CODEN: CHCOFS; ISSN: 1359-7345
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:115373
 GI



I

AB Viridiofungin A (I), a member of amino alkyl citrate antibiotics from *Trichoderma viride*, was enantioselectively synthesized in naturally occurring form for the first time, employing regio- and stereoselective opening of the chiral glycidate with vinylmagnesium bromide and alkene cross metathesis of the citric acid core and hexadec-15-en-8-one as key steps.


IT 147023-34-5P, (-)-Viridiofungin A
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (total synthesis of viridiofungin A via Sharpless asym. epoxidn.,
 regio- and stereoselective ring opening of a chiral glycidate and
 cross metathesis reactions)

RN 147023-34-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-((1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)amino-2,4,5-dideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.


L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 857285-37-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of viridiofungin A via Sharpless asym. epoxidn.,
 regio- and stereoselective ring opening of a chiral glycidate and
 cross metathesis reactions)
 RN 857285-37-1 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-3-C-((1,1-dimethylethoxy)carbonyl)-5-O-(1,1-dimethylethyl)-5-C-oxo-2-((1E)-9-oxo-1-hexadecenyl)-L-erythro-pentonoyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT:

THIS

23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:55191 CAPLUS
 DOCUMENT NUMBER: 142:134920
 TITLE: Preparation of phenylalanine derivatives as anti-HCV agents
 INVENTOR(S): Sudoh, Masayuki; Tsukuda, Takuo; Masubuchi, Miyako; Kawasaki, Kenichi; Murata, Takeshi; Watanabe, Fumiyo; Fukuda, Hiroshi; Koniyama, Susumu; Hayase, Tadakatsu
 PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 120 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

Instant App

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005372	A1	20050120	WO 2004-P9803	20040709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AW, A2, BY, KG, K2, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
RU: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, A2, BY, KG, K2, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004255633	A1	20050120	AU 2004-255633	20040709
CA 2317190	A1	20050120	CA 2004-2531790	20040709
EP 1661882	A1	20060531	EP 2004-747271	20040709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1819990	A	20060816	CN 2004-80019645	20040709
BR 2004012459	A	20061017	BR 2004-12459	20040709
NO 2005005986	A	20060213	NO 2005-5986	20051216
US 2006194870	A1	20060831	US 2005-563089	20051230
JP 2006232852	A	20060907	JP 2006-143804	20060524
PRIORITY APPN. INFO.:				
			JP 2003-272420	A 20030709
			JP 2003-34056	A 20030212
			JP 2005-504986	A3 20040212
			WO 2004-P9803	W 20040709

OTHER SOURCE(S): MARPAT 142:134920
 GI

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. I [wherein A = (CH₂)_n; n = 0-10; B = CH₂, CO, CH(OH), CH(NH₂), or (un)substituted C(=O)H; D = H or (un)substituted alkyl; E = H or alkyl; G = H or (un)substituted alkyl; R1-R3 = independently alkyl, alkenyl, alkynyl, (un)substituted OH, or NH₂], or prodrugs or pharmaceutically acceptable salts thereof are prepared as HCV replication inhibitors for the treatment of viral infectious diseases, especially liver diseases attributable to HCV infection. For example, the compound II was prepared in multi-step synthesis. II inhibited replicon with IC₅₀ of 0.002 μM in cow.

IT 827034-86-6P 827034-88-8P 827034-90-2P
 827034-92-4P 827034-94-6P 827034-96-8P
 827034-98-0P 827035-00-7P 827035-02-9P
 827035-04-1P 827035-06-3P 827035-08-5P
 827035-10-9P 827035-12-1P 827035-14-3P
 827035-16-5P 827035-18-7P 827035-20-1P
 827035-21-2P 827035-23-4P 827035-25-6P
 827035-27-8P 827035-28-9P 827035-29-0P
 827035-30-3P 827035-31-4P 827035-32-5P
 827035-33-6P 827035-34-7P 827035-35-8P
 827035-36-9P 827035-38-1P 827035-40-5P
 827035-41-6P 827035-42-7P 827035-43-8P
 827035-45-0P 827035-46-1P 827035-48-3P
 827035-50-7P 827035-51-8P 827035-53-0P
 827035-54-1P 827035-56-3P 827035-57-4P
 827035-59-6P 827035-61-0P 827035-62-1P
 827035-63-2P 827035-64-3P 827035-65-4P
 827035-66-5P 827035-67-6P 827035-68-7P
 827035-69-8P 827035-70-1P 827035-71-2P
 827035-72-3P 827035-73-4P 827035-74-5P
 827035-75-6P 827035-76-7P 827035-77-8P
 827035-78-9P 827035-79-0P 827035-80-3P
 827035-81-4P 827035-82-5P 827035-83-6P


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 827035-84-7P 827035-85-8P 827035-86-9P
 827035-87-0P 827035-88-1P 827035-89-2P
 827035-90-5P 827035-91-6P 827035-93-8P
 827035-95-0P 827035-97-2P 827035-99-4P
 827036-01-1P 827036-03-3P 827036-05-5P
 827036-07-7P 827036-09-9P 827036-10-2P
 827036-11-3P 827036-12-4P 827036-13-5P
 827036-14-6P 827036-15-7P 827036-16-8P
 827036-17-9P 827036-18-0P 827036-19-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
 (Drug candidate; prepn. of phenylalanine derivs. as anti-HCV agents)
 RN 827034-86-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827034-88-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827034-96-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-naphthalenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827034-98-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyclohexyloxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-00-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-methylpentyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827034-90-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(phenylmethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827034-92-4 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(2-butyryloxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827034-94-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[1,1'-biphenyl]-4-yl-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-02-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3,4-dimethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-04-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-chlorophenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-06-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-fluorophenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-08-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-pentylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-10-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-pyridinyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827035-12-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-chloro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-14-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827035-16-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2',4'-difluorol-1,1'-biphenyl)-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B

-Me


RN 827035-18-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-thienyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-20-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(trifluoromethyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-21-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyanophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-23-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-chlorophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-25-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-nitrophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-27-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-thienyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-29-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-chlorobiphenyl)-4-yl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-30-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-chlorophenoxy)phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-31-4 CAPLUS
CN D-erythro-Pentonic acid, 3-[(1S)-2-(4-butoxyphenyl)-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-32-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
propoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-33-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-propenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-34-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-35-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-11-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-36-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-42-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-heptadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-43-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-4-[(1E)-14-methyl-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-45-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-38-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-dodecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-40-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-11-phenyl-1-undecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-41-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1,15-hexadecadienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methybutoxyphenyl)ethyl]amino)-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-46-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylbutoxy)phenyl)ethyl]amino]-4-[(1E)-11-cyclohexyl-9-oxo-1-undecenyl]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B



RN 827035-48-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(4-methylphenyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 827035-50-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(4-methoxyphenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-51-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(trifluoromethylphenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-53-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-methylphenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-54-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(trifluoromethylphenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-56-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

—OMe

RN 827035-57-4 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-methyl[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-59-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(trifluoromethyl)[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

—CF3

RN 827035-61-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-methyl[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(1E)-9-oxo-1-hexadecenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-62-1 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B



PAGE 1-B


—OMe

RN 827035-63-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-64-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-fluorophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-65-4 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-(2'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-66-5 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B




RN 827035-67-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(dimethylamino)phenoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-69-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(phenylamino)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B




RN 827035-70-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(dimethylamino)[1,1'-biphenyl]-4-yl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 827035-71-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-cyano[1,1'-biphenyl]-4-yl)ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 827035-73-4 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(6-methoxy-3-pyridinyl)phenyl]ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

→ CN

RN 827035-72-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(4-morpholinyl)phenyl)ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


→ OMe

RN 827035-74-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(dimethylamino)sulfonyl](1,1'-biphenyl)-4-yl]ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




PAGE 1-B



RN 827035-75-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(methylaminophenyl)ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-76-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(5-pyrimidinyl)phenyl]ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 827035-77-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(methylthio)(1,1'-biphenyl)-4-yl]ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


→ SMe

RN 827035-78-9 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(5-methoxy-3-pyridinyl)phenyl]ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 827035-79-0 CAPLUS

CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-80-3 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(methylsulfonyl)1,1'-biphenyl)-4-yl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



PAGE 1-B



RN 827035-81-4 CAPLUS

CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-methoxy-5-pyrimidinyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-B




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827035-82-5 CAPLUS

CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(3-aminopropoxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-83-6 CAPLUS


CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(1-methyl-4-piperidinyl)oxylphenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-84-7 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-dimethylamino)propoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-85-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-pyridinylmethoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-B




RN 827035-86-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-(4-morpholinyl)ethoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-87-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-(1-piperazinyl)ethoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-88-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-(pyridinylmethyl)amino)propoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-A

PAGE 1-B

RN 827035-89-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-(4-methyl-1-piperazinyl)propoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 827035-90-5 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-(4-azidophenyl)-1-carboxyethyl]amino)-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-91-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(9-fluoren-9-ylmethoxy)carbonyl]amino)methyl]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-93-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(methylsulfonyl)amino]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-95-0 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(acetylamino)phenyl]-1-carboxyethyl]amino)-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-97-2 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(aminomethyl)phenyl]-1-carboxyethyl]amino)-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-99-4 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-[(aminomethyl)amino]phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-01-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-ethoxycarbonyl)-1H-1,2,3-triazol-1-yl]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

—(CH₂)₆ Me

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-09-9 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[1,1'-biphenyl]-4-yl-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-10-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-11-3 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[1,1'-biphenyl]-4-yl-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-03-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3-pyridinyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-05-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-15-fluoro-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-07-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-15-methoxy-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-12-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-13-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(2-hexynyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-14-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-propynyl oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-15-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-pentylnoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-16-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-pentylnoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827036-17-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(diethylamino)-2-butynyl oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

RN 827036-18-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-pentylnoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.
 Double bond geometry as shown.

RN 827036-19-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-decynyl oxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A

PAGE 1-B


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B

IT 827036-33-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of phenylalanine derivs. as anti-HCV agents)
 RN 827036-33-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-[(1S)-2-(1,1-dimethylethoxy)-2-oxo-1-[(4-phenoxyphenyl)methyl]ethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-20-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(6,6-dimethyl-2,4-heptadiynyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:701987 CAPLUS
DOCUMENT NUMBER: 141:230667
TITLE: Remedy for viral disease
INVENTOR(S): Aoki, Masahiro; Kato, Hideyuki; Sudoh, Masayuki;
Tsukuda, Taku: Matsubuchi, Miyako; Kawasaki, Kenichi
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 98 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071503	A1	20040826	WO 2004-JP1498	20040212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004211950	A1	20040826	AU 2004-211950	20040212
CA 2515370	A1	20040826	CA 2004-2515370	20040212
EP 1593378	A1	20051109	EP 2004-710509	20040212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007140	A	20060207	BR 2004-143804	20040212
CN 1835744	A	20060920	CN 2004-80004093	20040212
US 2006217434	A1	20060928	US 2005-544896	20050808
JP 2006232852	A	20060907	JP 2006-143804	20060524
PRIORITY APPLN. INFO.:			JP 2003-34056	A 20030212
			JP 2003-272420	A 20030709
			JP 2005-504986	A3 20040212
			WO 2004-JP1498	W 20040212

OTHER SOURCE(S): MARPAT 141:230667
AB It is intended to provide a medicinal composition for preventing or treating viral infection. A medicinal composition containing a compound, which has an extremely potent anti-HCV activity and an HCV amplification inhibitory effect and shows little cytotoxicity in vivo, is highly useful as a preventive/remedy for HCV.
IT 745782-39-2P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(remedy for viral disease)


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 744208-39-2 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methyl-2-butenoxy)phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 744208-61-5P 744208-62-6P 744208-63-7P
744208-64-8P 744208-65-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(remedy for viral disease)
RN 744208-61-5 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methyl-2-butenoxy)phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-62-6 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-2-methoxy-1-[(4-(3-methyl-2-butenoxy)phenyl)methyl]-2-oxoethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)-, 1-methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-63-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-4-(9-hydroxy-1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-64-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 744208-65-9 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenoxy)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-(10-hydroxy-9-oxo-1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



IT 744208-68-2P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(remedy for viral disease)
RN 744208-68-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 744208-69-3 CAPLUS
CN D-erythro-Pentonic acid, N5-[(1S)-2-amino-1-[(4-[(3-methyl-2-butenoxy)oxy]phenyl)methyl]-2-oxoethyl]amino]-3-C-carboxy-2,4,5-trideoxy-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-70-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxohexadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



IT 744208-66-0P 744208-67-1P 744208-69-3P
744208-70-6P 744208-71-7P 744208-72-8P
744208-73-9P 744208-74-0P 744208-75-1P
744208-76-2P 744208-77-3P 744208-78-4P
744208-92-2P 745782-40-5P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(remedy for viral disease)
RN 744208-66-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-67-1 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenoxy)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-(9-hydroxy-1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 744208-71-7 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenoxy)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-(1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-72-8 CAPLUS
CN D-erythro-Pentonic acid, 4-[9-[(2-aminoethoxy)imino]-1-hexadecenyl]-3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenoxy)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-73-9 CAPLUS
CN D-erythro-Pentonic acid,
3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenoxy)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-[9-(methoxyimino)-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A

NH₂


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-74-0 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-(4-butoxyphenyl)-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-75-1 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-2-(4-(2-butyloxy)phenyl)-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 744208-78-4 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-92-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3,4-dimethoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 745782-40-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxohexadecyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 744208-76-2 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-propenoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 744208-77-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-propoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 744208-91-1P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(remedy for viral disease)
RN 744208-91-1 CAPLUS
CN D-erythro-Pentonic acid, 5-[(1S)-1-[(4-(2-butynyoxy)phenyl)methyl]-2-(1,1-dimethyllethoxy)-2-oxoethylamino]-3-C-[(1,1-dimethyllethoxy)carbonyl]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)-, 1,1-dimethyllethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:689188 CAPLUS
 DOCUMENT NUMBER: 141:366432
 TITLE: Total synthesis of (3S,4S,2'S)- and (3R,4R,2'S)-viridiofungin A triester
 AUTHOR(S): Pollex, Annett; Abraham, Lars; Mueller, Jana;
 Hiersemann, Martin
 CORPORATE SOURCE: Institut fuer Organische Chemie, Technische
 Universitaet Dresden, Dresden, D-01062, Germany
 SOURCE: Tetrahedron Letters (2004), 45(37), 6915-6918
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:366432

AB The total synthesis of an alkylcitrate secondary metabolite from the fungi Trichoderma viride is described. An ester dienolate [2,3]-Wittig rearrangement and a S. Julia-Kocienski olefination served as key C/C-connecting transformations. The afforded two diastereomers were separated by preparative reversed-phase HPLC to provide the (3S,4S,2'S)-viridiofungin A triester and the (3R,4R,2'S)-viridiofungin A triester as single diastereo- and enantiomers. The highly convergent synthesis consist of a longest linear sequence of 17 steps.

IT 777891-06-2P 777891-07-3P
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
 (total synthesis and resolution of viridiofungin A triester and its unnatural diastereomer via diastereoselective ester dienolate Wittig rearrangement, Julia-Kocienski olefination and HPLC)

RN 777891-06-2 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-erythro-pentonoyl]-, methyl ester (9CI)
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



L3 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:66706 CAPLUS
 DOCUMENT NUMBER: 132:202567
 TITLE: Isolation and characterization of novel inhibitors of sphingolipid synthesis: australifungin, viridiofungins, rustemicin, and khafrefungin
 AUTHOR(S): Mandala, Suzanne M.; Harris, Guy H.
 CORPORATE SOURCE: Department of Infectious Disease, Merck Research Laboratories, Rahway, NJ, 07065-4607, USA
 SOURCE: Methods in Enzymology (2000), 311 (Sphingolipid Metabolism and Cell Signaling, Part A), 335-348
 PUBLISHER: Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB A method to identify sphingolipids and a detailed protocol for the isolation of australifungin are described. Brief descriptions of the isolation of viridiofungins, khafrefungin, and rustemicin are included. The bioact. of the inhibitors of sphingolipid synthesis is examined

by ceramide synthase, serine palmitoyltransferase, and inositol phosphoceramide synthase inhibition tests. (c) 2000 Academic Press.

IT 147023-34-5, Viridiofungin A
 RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); ANST (Analytical study); BIOL (Biological study); PREP (Preparation) (isolation and characterization of novel inhibitors of sphingolipid synthesis)

RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


$R_1 = OH$
 $R_2 = OH$
 $R_3 = OH$

$n = 6$
 $D = heptyl$

Searched by Jason M. Nolan, Ph.D.


L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 777891-07-3 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-threo-pentonoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:282451 CAPLUS
 DOCUMENT NUMBER: 131:19258
 TITLE: Synthesis of viridiofungin A and its absolute structure
 AUTHOR(S): Esumi, T.; Iwabuchi, Y.; Irie, H.; Hatakeyama, S.
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagasaki University, Nagasaki, Japan
 SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1997), 39th, 409-414
 PUBLISHER: Nippon Kagakkaishi
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese



AB Viridiofungin A was isolated from a strain of Trichoderma viride Pers. (Fungi, Hyphomycetes) together with Viridiofungin B and C after screening for substances that exhibit cholesterol lowering activity. These Viridiofungins, a novel family of squalene synthase inhibitors, have unique structures consisting of a common citric acid moiety having C-16 long chain and an aromatic amino acid residue such as tyrosine, phenylalanine, and tryptophane. However, the absolute structures of these compds. have not been determined yet. We describe the first synthesis of Viridiofungin A tri-Me ester which allowed us to determine its absolute configuration to be 3S,4S,2'S-. Katsuki-Sharpless asym. epoxidn. of the trisubstituted allylic alc. [trans-MPMOCH₂CH₂(CH₂OMPM):CH₂OH; MPM = p-methoxybenzyl] followed by regio- and stereoselective opening of

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (I) to give the diol (II) from which two epimeric aldehydes (III and IV) were prepd. selectively. Upon attachment of the long chain portion by Wittig olefination reaction followed by functional group transformations, the aldehyde III and IV gave the alc. (V; R = H, R1 = CH2OH) and (V; R = CH2OH, R1 = H) resp. After Jones oxidn. of V (R = H, R1 = CH2OH), the resulting carboxylic acid was condensed with L- and D-tyrosine Me ester


to give (39,48,2'S)-viridiofungin A tri-Me ester (V; R = H, R1 = L-Tyr-OMe) and (38,48,2'R)-viridiofungin A tri-Me ester (V; R = H, R1 = D-Tyr-OMe) (Viridiofungin A deriv.). Similarly, (39,4R,2'S)-viridiofungin A tri-Me ester (V; R = L-Tyr-OMe, R1 = H) and (38,4R,2'R)-viridiofungin A tri-Me ester (V; R = D-Tyr-OMe, R1 = H) were also synthesized from V (R = H, R1 = CH2OH).

CH2OH. Now we can conclude that the abs. configuration of natural viridiofungin A is 38,49,2'S by comparison (1H NMR and TLC) of four synthetic samples with natural Viridiofungin A tri-Me ester in addn. to information that the tyrosine-configuration is L.

IT 204524-70-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (total synthesis of viridiofungin A having cholesterol-lowering and squalene synthase inhibitory activity and its absolute structure)

RN 204524-70-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1R)-1-
 [(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-
 1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



IT 147023-37-8P 204524-71-0P 204524-72-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (viridiofungin A stereoisomer; total synthesis of viridiofungin A having cholesterol-lowering and squalene synthase inhibitory activity and its absolute structure)


RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-
 [(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.




L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1-hexadecenyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 204524-71-0 CAPLUS
 CN L-threo-Pentonic acid,
 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-[(4-
 hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 204524-72-1 CAPLUS
 CN L-threo-Pentonic acid,
 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1R)-1-[(4-
 hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:7961 CAPLUS
 DOCUMENT NUMBER: 130:65343
 TITLE: Physiologically active substances TKR2449 analogs
 process for producing the same, and microorganism
 INVENTOR(S): Takesako, Kezutoh; Ueno, Mitsuhiro; Awazu, Naoyuki;
 Uno, Yoko; Kato, Ikunoshin

PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856755	A1	19981217	WO 1998-JP2530	19980609
W: AU, BE, CA, CN, CZ, HU, JP, KR, MX, NO, PL, RO, SK, US, AM, AZ, BR, BS, DE, ES, FR, GB, IT, RU, TJ, TM				
BT, ES, FR, GB, IT				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9875520	A	19981230	AU 1998-75520	19980609
EP 1002793	A1	20000524	EP 1998-923171	19980609
EP 1002793	B1	20030924		
R: DE, ES, FR, GB, IT				
ES 2209140	T3	20040616	ES 1998-923171	19980609
US 6303350	B1	20011016	US 2000-445543	20000307
PRIORITY APPLN. INFO.:				
			JP 1997-168011	A 19970609
			WO 1998-JP2530	W 19980609

GI



NOT IACV

AB Novel physiol. active substances TKR2449 analogs (I: R1, R2, and R3 are the same or different and each represents hydrogen or C alkyl; and R4 represents linear or branched C alkyl or alkenyl) useful as remedies for fungal infection or immunol. diseases. They are manufactured with

Aureobasidium sp. by fermentation and chemical synthesis. The physiol. and morphol. characteristics of Aureobasidium sp. were given.

IT 217648-17-4P, TKR 2449
 RL: BPN (Biosynthetic preparation); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (physiol. active substances TKR2449, process for producing same and microorganism)

RN 217648-17-4 CAPLUS


103- Compd 44 - P 22

10/563,089

02/28/2007

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Butanedioic acid, 2-[1-[[1-carboxy-2-[(4-[(3-methyl-2-but enyl)oxy]phenyl)ethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry unknown.
 Currently available stereo shown.




-OW
W = linear
alkenyl

proviso-
claims 4+5

IT 217648-18-5P, TKR 2449 methyl ester
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (physiol. active substances TKR2449, process for producing same and microorganism)


RN 217648-18-5 CAPLUS
 CN Butanedioic acid, 2-hydroxy-2-[1-[[2-methoxy-1-[(4-[(3-methyl-2-but enyl)oxy]phenyl)methyl]-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl-, dimethyl ester (9CI) (CA INDEX NAME)

Double bond geometry unknown.
 Currently available stereo shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 1998:107242 CAPLUS
 DOCUMENT NUMBER: 128:230160
 TITLE: Synthesis of viridiofungin A trimethyl ester and determination of the absolute structure of viridiofungin A
 AUTHOR(S): Esumi, Tomoyuki; Iwabuchi, Yoshiharu; Irie, Hiroshi; Hatakeyama, Susumi
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagasaki University, Nagasaki, 852, Japan
 SOURCE: Tetrahedron Letters (1998), 39(8), 877-880
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 128:230160
 GI




AB Four diastereoisomeric tri-Me esters of viridiofungin A, a member of novel family of aminoacyl alkyl citrate compds., were synthesized in a highly stereoselective manner and the absolute configuration of natural viridiofungin A was determined to be 3S,4S,2'S as depicted in triacid I.

IT 147023-34-5
 RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
 (absolute configuration of viridiofungin A via asym. total synthesis of its tri-Me ester)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 147023-37-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (absolute configuration of viridiofungin A via asym. total synthesis of its tri-Me ester)
 RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



IT 204524-70-9P 204524-71-0P 204524-72-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (absolute configuration of viridiofungin A via asym. total synthesis of its tri-Me ester)
 RN 204524-70-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1R)-1-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 204524-71-0 CAPLUS
 CN L-threo-Pentonic acid,
 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 204524-72-1 CAPLUS
 CN L-threo-Pentonic acid,
 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1R)-1-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:308114 CAPLUS

DOCUMENT NUMBER: 127:31288

TITLE: Viridiofungins, novel inhibitors of sphingolipid synthesis

AUTHOR(S): Mandala, Suzanne M.; Thornton, Rosemary A.; Frommer, Beth R.; Dreikorn, Sarah; Kurtz, Myra B.

CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Journal of Antibiotics (1997), 50(4), 339-343

CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Viridiofungins are broad spectrum antifungal agents that inhibit the squalene synthase in vitro, but do not specifically inhibit fungal ergosterol synthesis in whole cells, indicating a different mode of action

for antifungal activity. In this report, we show that viridiofungins are potent in vitro inhibitors of serine palmitoyltransferase, the first committed enzyme in sphingolipid biosynthesis, and their antifungal activity is due to inhibition of sphingolipid synthesis. Addnl. related components with the same mode of action were isolated from the producing culture, Trichoderma viride, and inhibition of the serine palmitoyltransferase and antifungal activity is presented.


IT 147023-35-6, Viridiofungin B

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); BIOL (Biological study) (antifungal activity of viridiofungins with phytosphingosine or stearalamine)

RN 147023-35-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-((1S)-1-carboxy-2-(4-phenylethyl)amino)-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

IT 147023-34-5, Viridiofungin A 147023-36-7, Viridiofungin

C 158589-77-6, Viridiofungin A4 158589-79-8,

Viridiofungin B2 158589-81-2, Viridiofungin Al

158589-82-3, Viridiofungin A3 158589-84-5, Viridiofungin


A2

RL: BAC (Biological activity or effector, except adverse); BSU
(BiologicalL3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
study, unclassified); BIOL (Biological study)

(viridiofungins, novel inhibitors of sphingolipid synthesis)


RN 147023-34-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-((1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)amino)-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

RN 147023-36-7 CAPLUS


CN D-erythro-Pentonic acid, 3-C-carboxy-5-((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 158589-77-6 CAPLUS


CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl-2-[(10-oxo-2-nonenadecenyl)-2-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 158589-79-8 CAPLUS

CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-81-2 CAPLUS

CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-82-3 CAPLUS


CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 158589-84-5 CAPLUS
CN Butanedioic acid,
2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-1-2-heptadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




IT 160065-77-0P, Viridiofungin A 1-methyl ester 160065-78-1P
, Viridiofungin A 1'-methyl ester 160065-79-2P, Viridiofungin A
1,1'-dimethyl ester 190718-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(viridiofungins, novel inhibitors of sphingolipid synthesis)
RN 160065-77-0 CAPLUS
CN Butanedioic acid,
2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-1-10-oxo-2-heptadecenyl-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 160065-78-1 CAPLUS
CN Butanedioic acid,
2-hydroxy-2-[1-[(1-((4-hydroxyphenyl)methyl)-2-methoxy-2-oxoethyl)amino]carbonyl]-10-oxo-2-heptadecenyl- (9CI) (CA INDEX NAME)




IT 160065-79-2 CAPLUS
CN Butanedioic acid,
2-hydroxy-2-[1-[(1-((4-hydroxyphenyl)methyl)-2-methoxy-2-oxoethyl)amino]carbonyl]-10-oxo-2-heptadecenyl-, 4-methyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 190718-93-5 CAPLUS
CN Butanedioic acid,
2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-1-10-oxoheptadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)

Currently available stereo shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

1997-308113 CAPLUS

ACCESSION NUMBER: 1997-308113 CAPLUS
DOCUMENT NUMBER: 1271-2922
TITLE: Antimicrobial activity of viridiofungins
AUTHOR(S): Onishi, J. S.; Milligan, J. A.; Basilio, A.; Bergstrom, J.; Curotto, J.; Huang, L.; Meinz, M.; Nallin-Omstead, M.; Pelaez, F.; Rew, D.; Salvatore, M.; Thompson, J.; Vicente, F.; Kurtz, M. B.
CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SOURCE: Journal of Antibiotics (1997), 50(4), 334-338
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A family of aminoacyl'alkyl citrate compds. called viridiofungins, are novel squalene synthase inhibitors. The compds. have broad spectrum fungicidal activity but lack antibacterial activity. Although the compds. inhibit squalene synthase, the first committed step in ergosterol biosynthesis, results presented show that inhibition of fungal growth is not related to inhibition of ergosterol synthesis.

IT 147023-34-5, Viridiofungin A 147023-35-6, Viridiofungin B 147023-36-7, Viridiofungin C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(viridiofungins: antimicrobial activity)
RN 147023-34-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 147023-35-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

1995-1494 CAPLUS

ACCESSION NUMBER: 124:139477
 DOCUMENT NUMBER:
 TITLE:
 AUTHOR(S): Huang, Leeyuan; Lingham, Russell B.; Harris, Guy H.; Singh, Sheo B.; Dufresne, Claude; Nallin-Omstead, Mary; Bills, Gerald F.; Mojena, Marina; Sanchez, Manuel; et al.

CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Canadian Journal of Botany (1995), 73(Suppl. 1, Sect. E-H, Fifth International Mycological Congress, Sect. E-H, 1994), S898-S906

CODEN: CJBOAW; ISSN: 0008-4026
 PUBLISHER: National Research Council of Canada
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Several potent inhibitors of squalene synthetase have been discovered. Zaragozic acid A is produced by several fungi; zaragozic acid B is produced by several strains of *Sporomella intermedia*; zaragozic acids C,

E, and F are produced by *Leptodonitidium elutius*; zaragozic acids D and D2 are produced by *Amuroascus niger*. L-731,120 and L-731,128 are minor components and coproduced with zaragozic acids A and B, resp. Viridiofungins A, B, and C are produced by *Trichoderma viride*. Viridiofungin A is also produced by an unidentified sterile fungus. Several of the zaragozic acids are also potent inhibitors of farnesyl-protein transferase (FPTase). Inhibitors of FPTase may act as potential anticancer drugs. Chaetomelic acids A and B are produced by a fungus, *Chaetomella acutiseta*, while fusidienol is produced by *Fusidium griseum*. All three compds. are potent inhibitors of FPTase. Our experiences suggest that many novel inhibitors of both squalene synthase and FPTase are produced within a diverse phylogenetic array of filamentous fungi. Several of the zaragozic acids are potent inhibitors of both FPTase and squalene synthases. This is consistent with our observations that zaragozic acids and chaetomelic acids share some structural similarity.

IT 147023-34-5, Viridiofungin A 147023-35-6, Viridiofungin B 147023-36-7, Viridiofungin C
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES


(Uses)
 (new fungal metabolites inhibiting squalene synthases and farnesyl-protein transferase as potential antihypercholesterolemics and anticancer agents)

RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Double bond geometry as shown.




RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

1995-261315 CAPLUS

ACCESSION NUMBER: 122:54157
 DOCUMENT NUMBER:
 TITLE:
 INVENTOR(S): Biologically active compounds isolated from aerobic fermentation of *Trichoderma viride*
 Harris, Guy H.; Zink, Deborah; Jones, E. Tracy T.; Kong, Yu L.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 18 pp. Cont.-in-part of U.S. Ser. No. 739,758, abandoned.
 CODEN: USXXAM

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5364948	A	19941115	US 1993-15498	19930209
WO 9418157	A1	19940818	WO 1994-US792	19940125
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9462315	A	19940829	AU 1994-62315	19940125
PRIORITY APPLN. INFO.:			US 1991-739758	B2 19910802
			US 1992-907730	B2 19920709
			US 1993-15498	A 19930209
			WO 1994-US792	W 19940125


OTHER SOURCE(S): MARPAT 122:54157
 AB This invention relates to compds. isolated from an aerobic fermentation of *T. viride* MF5628, ATCC 74084, which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. These compds. are also potent antifungal agents. Additionally, they inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining these compds.

IT 147023-34-5P 147023-35-6P 147023-37-8P
 158589-77-6P 158589-79-8P 158589-80-1P
 158589-82-3P 158589-84-5P 158589-85-6P
 158589-86-7P 160065-77-0P 160065-78-1P
 160065-79-2P 160065-80-5P 160065-81-6P
 RL: BMF (Bioindustrial manufacture); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (biol. active compds. isolated from aerobic fermentation of *Trichoderma viride*)

RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-((1E)-9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
Double bond geometry as shown.



RN 147023-35-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 147023-37-8 CAPLUS
CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-77-6 CAPLUS
CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl-1]-10-oxo-2-nonadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-79-8 CAPLUS
CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-2-heptadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-80-1 CAPLUS
CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-82-3 CAPLUS
CN Butanedioic acid, 2-[(1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl-1]-10-oxo-2-hexadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-84-5 CAPLUS
CN Butanedioic acid, 2-[(1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl-1]-2-heptadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-85-6 CAPLUS
CN Butanedioic acid, 2-[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-hexadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-86-7 CAPLUS
CN Butanedioic acid, 2-[(1-carboxy-2-phenylethyl)amino]carbonyl-10-hydroxy-2-heptadecenyl-2-hydroxy- (9CI) (CA INDEX NAME)




RN 160065-77-0 CAPLUS
CN Butanedioic acid, 2-[(1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl-1]-10-oxo-2-heptadecenyl-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)



RN 160065-78-1 CAPLUS
CN Butanedioic acid, 2-hydroxy-2-[(1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl)amino]carbonyl]-10-oxo-2-heptadecenyl- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 160065-79-2 CAPLUS

CN Butanedioic acid, 2-[1-[(1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl)amino]carbonyl]-10-oxo-2-heptadecenyl-, 4-methyl ester (9CI) (CA INDEX NAME)



RN 160065-80-5 CAPLUS

CN Butanedioic acid, 2-[1-[(1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl)amino]carbonyl]-10-oxo-2-heptadecenyl-, 2-hydroxy- (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:124835 CAPLUS

DOCUMENT NUMBER: 122:8148

TITLE: Biologically active compounds isolated from aerobic fermentation of *Trichoderma viride*

INVENTOR(S): Harris, Guy H.; Milligan, James A.; Lingham, Russell B.; Zink, Deborah; Diez, Maria Teresa; Peleaz, Fernando; Jones, E. Tracy Turner; Meinz, Maria Sandrino; Bergstrom, James D.; et al.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418157	A1	19940818	WO 1994-U5792	19940125
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, NE, SN, TD, TG				
US 5364948	A	19941115	US 1993-15498	19930209
AU 9462315	A	19940829	US 1994-62315	19940125
PRIORITY APPLN. INFO.: US 1993-15498				
		US 1991-739758	B2	19910802
		US 1992-907730	B2	19920709
		WO 1994-U5792	W	19940125

AB This invention relates to compds. of structural formula compound Q (I) isolated from an aerobic fermentation of *Trichoderma viride* MF5628, ATCC 74084.

which are squalene synthase inhibitors and thus useful as cholesterol-lowering agents. These compds. are also potent antifungal agents. Addnl., they inhibit farnesyl protein transferase and proliferation of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining compds. of structural formula I.

IT 158589-76-5P 158589-77-6P 158589-84-5P


RL: BAC (Biological activity or effector, except adverse); BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(biol. active compds. isolated from aerobic fermentation of *Trichoderma viride*)RN 158589-76-5 CAPLUS
CN Butanedioic acid, 2-[1-[(1-carboxy-2-(1H-indol-3-yl)ethyl)amino]carbonyl]-10-hydroxy-2-heptadecenyl-, 2-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

RN 160065-81-6 CAPLUS

CN Butanedioic acid, 2-[1-[(1H-indol-3-ylmethyl)amino]carbonyl]-10-hydroxy-2-heptadecenyl-, 2-hydroxy- (9CI) (CA INDEX NAME)






L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)

RN 158589-77-6 CAPLUS


CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2-nonadecenyl-, 2-hydroxy- (9CI) (CA INDEX NAME)

IT 158589-79-0P 158589-80-1P 158589-81-2P
158589-82-3P 158589-85-6P 158589-86-7PRL: BAC (Biological activity or effector, except adverse); BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(biol. active compds. isolated from aerobic fermentation of


L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 158589-79-8 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-80-1 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-81-2 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-82-3 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)


L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 159530-24-2 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-2,9-heptadecadienyl]-2-hydroxy- (9CI) (CA INDEX NAME)




L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-85-6 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-86-7 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158599-13-4 CAPLUS
 CN Butanedioic acid, 2-[1-[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2,7-hexadecadienyl]-2-hydroxy- (9CI) (CA INDEX NAME)

CM 1


CRN 158589-82-3
 CMF C30 H43 N O10

L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:4128 CAPLUS
 DOCUMENT NUMBER: 120:4128
 TITLE: Isolation and structure elucidation of viridiofungins A, B and C
 AUTHOR(S): Harris, Guy H.; Jones, E. Tracy; Meinz, Maria S.; Nallin-Omstead, Mary; Helms, Gregory L.; Bills, Gerald F.; Zink, Deborah; Wilson, Kenneth E.
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Tetrahedron Letters (1993), 34(33), 5235-8
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The isolation and structure elucidation of 3 members of a novel family of amino acid-containing alkyl citrates, viridiofungins A, B, and C, from Trichoderma viride are described. They are potent, broad spectrum antifungal agents and in vitro inhibitors of squalene synthase.


IT 147023-34-5, Viridiofungin A 147023-35-6, Viridiofungin B 147023-36-7, Viridiofungin C
 RL: BIOL (Biological study)
 (from Trichoderma viride)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



IT 147023-37-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and structure of)

RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hypercholesterolemia, for inhibition of farnesyl-protein transferase, or for inhibiting fungal growth are claimed. I may be prep'd. with Trichoderma viride ATCC 74084. Four I compd. were prep'd. and tested for inhibition of squalene synthase (IC50 0.29-41.6 µg/mL) and farnesyl transferase (IC50 3.3-8 µM) as well as inhibition of fungal growth.


IT 147023-37-8P
 RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
 (manufacture of, with Trichoderma viride, for hypocholesteremic and antifungal)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:183428 CAPLUS
 DOCUMENT NUMBER:
 TITLE: Cholesterol-lowering agents, their manufacture with Trichoderma, and their use as fungicides or as medicaments

INVENTOR(S): Mary Meinz, Maria Sandrino; Pelaez, Fernando; Omstead,


Nallin; Milligan, James A.; Diez, Maria Teresa; Onishi, Janet C.; Bergstrom, James D.; Jenkins, Rosalind F.; Harris, Guy H.; et al.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 22 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 526936	A2	19930210	EP 1992-202300	19920725
EP 526936	A3	19930505		
R: CH, DE, FR, GB, IT, LI, NL				
CA 2074999	A1	19930203	CA 1992-2074999	19920730
JP 07173123	A	19950711	JP 1992-206802	19920803
PRIORITY APPLN. INFO.:			US 1991-739758	A 19910802
			US 1991-739932	A 19910802
			US 1991-739950	A 19910802
			US 1992-907730	A 19920709

OTHER SOURCE(S): MARPAT 118:183428
 GI




IDS A1

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

 $\text{G} = (\text{CH}_2)_7\text{-indol}$

RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.




IT 147023-38-9P 147023-39-OP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for hypocholesteremic and antifungal)
 RN 147023-38-9 CAPLUS
 CN Butanediioic acid, 2-hydroxy-2-[(1-[(2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino)carbonyl]-10-oxo-2-heptadecenyl]-, dimethyl ester (9CI) (CA INDEX NAME)

$\text{G} = \text{CH}_2\text{-Ph-OH}$

 $\text{G} = \text{CH}_2\text{-Ph}$

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

 $G = \text{CH}_2-\text{Ph}$

RN 147023-39-0 CAPLUS
 CN Butanedioic acid, 2-hydroxy-2-[1-[(1-(1H-indol-3-ylmethyl)-2-methoxy-2-oxoethyl)aminocarbonyl]-10-oxo-2-heptadecenyl], dimethyl ester (9CI)
 (CA INDEX NAME)

